EGFL8 (Epidermal Growth Factor-like protein 8) is a secreted protein belonging to the epidermal growth factor (EGF)-like superfamily, characterized by conserved EGF-like domains involved in cell signaling and adhesion. It shares structural homology with other EGFL family members, such as EGFL7. but exhibits distinct functional roles. EGFL8 is implicated in regulating cellular processes like proliferation, migration, and angiogenesis, with emerging evidence linking it to tumorigenesis and tissue remodeling.
Research on EGFL8 has gained momentum due to its potential role in cancer progression. Studies suggest its overexpression in certain malignancies, including breast and colorectal cancers, where it may promote tumor cell survival and metastasis by interacting with extracellular matrix components or modulating signaling pathways like PI3K/AKT or MAPK. Its expression in the tumor microenvironment also hints at roles in immune evasion or angiogenesis.
EGFL8 antibodies are crucial tools for detecting and quantifying EGFL8 expression in biological samples, enabling investigations into its spatial distribution and functional mechanisms. Polyclonal and monoclonal antibodies targeting specific epitopes are used in techniques such as Western blotting, immunohistochemistry (IHC), and ELISA. These antibodies aid in exploring EGFL8's diagnostic or prognostic value in cancers and its therapeutic targeting potential. However, challenges remain in elucidating its precise molecular interactions and validating its clinical relevance across diverse pathologies. Ongoing research aims to refine antibody specificity and explore therapeutic applications, such as blocking EGFL8-mediated oncogenic pathways.